Thurston Springer Miller Herd & Titak Inc. Makes New $127,000 Investment in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,107 shares of the biotechnology company’s stock, valued at approximately $127,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in Cerevel Therapeutics in the first quarter worth $26,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Cerevel Therapeutics during the 4th quarter valued at $71,000. Centaurus Financial Inc. bought a new stake in shares of Cerevel Therapeutics during the 4th quarter valued at $119,000. Virtu Financial LLC bought a new position in Cerevel Therapeutics in the 4th quarter worth about $246,000. Finally, Aigen Investment Management LP bought a new position in Cerevel Therapeutics in the 4th quarter worth about $348,000. Institutional investors own 87.73% of the company’s stock.

Insider Buying and Selling

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total value of $1,029,500.00. Following the sale, the director now directly owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by insiders.

Cerevel Therapeutics Stock Performance

NASDAQ CERE remained flat at $44.96 during trading on Tuesday. The company has a market capitalization of $8.19 billion, a P/E ratio of -16.47 and a beta of 1.40. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22. The stock’s fifty day moving average is $41.77 and its two-hundred day moving average is $41.93. Cerevel Therapeutics Holdings, Inc. has a 1 year low of $19.59 and a 1 year high of $44.99.

Cerevel Therapeutics (NASDAQ:CERE) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). On average, equities research analysts anticipate that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current year.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.